PTC Therapeutics, Inc. (PTCT) Q3 2026 earnings results
PTC Therapeutics, Inc. (PTCT) reported Q3 2026 results on Oct 29, 2026, 4:10:20 PM ET: GAAP EPS -$0.62 vs. $0.30 expected (miss by $0.92); revenue $357.81M vs. $305.01M expected (beat by 17.3%). Outlook: Full-year 2026 total revenue guidance increased to $1.29 to $1.32 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.62 | $0.30 | Miss by $0.92 |
| Revenue | $357.81M | $305.01M | Beat by 17.3% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 4:10:20 PM ET. Nexqual published them 88 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 69.6% from $211.01M; GAAP diluted EPS was -$0.62 vs. $0.20.
Stock reaction
The results came out after the market closed. PTCT closed at $64.46 on October 29, 2026, before the results. The first trading session after the release is Friday, October 30, 2026; this page shows the reaction once trading starts (pre-market and after-hours prices are not included).
Questions and answers
Did PTC Therapeutics, Inc. beat earnings expectations?
No. PTC Therapeutics, Inc. reported GAAP EPS of -$0.62 against an average analyst estimate of $0.30 (miss by $0.92), and revenue of $357.81M against $305.01M expected (beat by 17.3%).
What were PTC Therapeutics, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.62 and revenue of $357.81M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 69.6% from $211.01M; GAAP diluted EPS was -$0.62 vs. $0.20.
When did PTC Therapeutics, Inc. report Q3 2026 earnings?
Oct 29, 2026, 4:10:20 PM ET, in an SEC 8-K filing (Item 2.02).
How did PTCT stock react to the earnings?
The results came out after the market closed. PTCT closed at $64.46 on October 29, 2026, before the results. The first trading session after the release is Friday, October 30, 2026; this page shows the reaction once trading starts (pre-market and after-hours prices are not included).
What did PTC Therapeutics, Inc. say about its outlook?
Full-year 2026 total revenue guidance increased to $1.29 to $1.32 billion.
More on PTCT
PTCT stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:07 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt